Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Regenerative Medical Technology (RMTG) Depreciation & Amortization (CF) (2019 - 2025)

Historic Depreciation & Amortization (CF) for Regenerative Medical Technology (RMTG) over the last 7 years, with Q3 2025 value amounting to $76078.0.

  • Regenerative Medical Technology's Depreciation & Amortization (CF) fell 1435.36% to $76078.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $154912.0, marking a year-over-year decrease of 5513.74%. This contributed to the annual value of $220559.0 for FY2024, which is 2887.53% down from last year.
  • As of Q3 2025, Regenerative Medical Technology's Depreciation & Amortization (CF) stood at $76078.0, which was down 1435.36% from $54832.0 recorded in Q2 2025.
  • Regenerative Medical Technology's Depreciation & Amortization (CF)'s 5-year high stood at $98667.0 during Q3 2023, with a 5-year trough of -$27812.0 in Q4 2024.
  • In the last 5 years, Regenerative Medical Technology's Depreciation & Amortization (CF) had a median value of $51814.0 in 2025 and averaged $47735.9.
  • As far as peak fluctuations go, Regenerative Medical Technology's Depreciation & Amortization (CF) skyrocketed by 1746250.0% in 2022, and later plummeted by 12869.23% in 2024.
  • Over the past 5 years, Regenerative Medical Technology's Depreciation & Amortization (CF) (Quarter) stood at $27511.0 in 2021, then soared by 85.94% to $51155.0 in 2022, then surged by 89.49% to $96932.0 in 2023, then plummeted by 128.69% to -$27812.0 in 2024, then skyrocketed by 373.54% to $76078.0 in 2025.
  • Its last three reported values are $76078.0 in Q3 2025, $54832.0 for Q2 2025, and $51814.0 during Q1 2025.